Terms: = Leukemia AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2 AND Treatment
19 results:
1. Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (cd32)-dependent Manner.
Takami M; Aoki T; Nishimura K; Tanaka H; Onodera A; Motohashi S
Cancer Res Commun; 2024 Feb; 4(2):446-459. PubMed ID: 38319156
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract] [Full Text] [Related]
3. Development of Anti-cd32b Antibodies with Enhanced Fc Function for the treatment of B and Plasma Cell Malignancies.
Lu H; Molony RD; Chen D; Jang S; Wolf B; Ewert S; Flaherty M; Xu F; Isim S; Shim Y; Dornelas C; Balke N; Leber XC; Scharenberg M; Koelln J; Choi E; Ward R; Johnson J; Calzascia T; Isnardi I; Williams JA; Lindenbergh PL; van de Donk NWCJ; Mutis T; Huet H; Lees E; Meyer MJ
Mol Cancer Ther; 2020 Oct; 19(10):2089-2104. PubMed ID: 32847974
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
Parting O; Langer S; Kuepper MK; Wessling C; Li S; Braunschweig T; Chatain N; Maié T; Costa IG; Crysandt M; Huber M; Brümmendorf TH; Koschmieder S; Schemionek M
Leukemia; 2020 Oct; 34(10):2635-2647. PubMed ID: 32684632
[TBL] [Abstract] [Full Text] [Related]
5. Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia.
Natarajan H; Kumar L; Bakhshi S; Sharma A; Velpandian T; Kabra M; Gogia A; Ranjan Biswas N; Gupta YK
Leuk Lymphoma; 2019 Feb; 60(2):418-425. PubMed ID: 30124353
[TBL] [Abstract] [Full Text] [Related]
6. Universal monitoring of minimal residual disease in acute myeloid leukemia.
Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
[TBL] [Abstract] [Full Text] [Related]
7. PHAGOCYTOSIS AND EXPRESSION OF FCg-RECEPTORS AND CD180 ON MONOCYTES IN CHRONIC LYMPHOCYTIC leukemia.
Tsertsvadze T; Mitskevich N; Bilanishvili A; Girdaladze D; Porakishvili N
Georgian Med News; 2017 Sep; (270):88-93. PubMed ID: 28972490
[TBL] [Abstract] [Full Text] [Related]
8. FcγRIIb expression in early stage chronic lymphocytic leukemia.
Bosch R; Mora A; Vicente EP; Ferrer G; Jansà S; Damle R; Gorlatov S; Rai K; Montserrat E; Nomdedeu J; Pratcorona M; Blanco L; Saavedra S; Garrido A; Esquirol A; Garcia I; Granell M; Martino R; Delgado J; Sierra J; Chiorazzi N; Moreno C
Leuk Lymphoma; 2017 Nov; 58(11):2642-2648. PubMed ID: 28372509
[TBL] [Abstract] [Full Text] [Related]
9. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.
Lin Y; Zhang L; Cai AX; Lee M; Zhang W; Neuberg D; Canning CM; Soiffer RJ; Alyea EP; Ritz J; Hacohen N; Means TK; Wu CJ
J Clin Invest; 2011 Apr; 121(4):1574-84. PubMed ID: 21403403
[TBL] [Abstract] [Full Text] [Related]
10. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.
Majeti R
Oncogene; 2011 Mar; 30(9):1009-19. PubMed ID: 21076471
[TBL] [Abstract] [Full Text] [Related]
11. All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias.
Barber N; Belov L; Christopherson RI
Leuk Res; 2008 Feb; 32(2):315-22. PubMed ID: 17561254
[TBL] [Abstract] [Full Text] [Related]
12. [Effect of recombinant human granulocyte colony-stimulating factor on neutrophil morphology, function and phenotype in patients with acute leukemia undergoing chemotherapy].
Huang HH; Zhong JH; Han XF; Xuan ZH; Han JY; Chen FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1033-7. PubMed ID: 16403274
[TBL] [Abstract] [Full Text] [Related]
13. Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter.
Ebbinghaus C; Al-Jaibaji A; Operschall E; Schöffel A; Peter I; Greber UF; Hemmi S
J Virol; 2001 Jan; 75(1):480-9. PubMed ID: 11119616
[TBL] [Abstract] [Full Text] [Related]
14. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
Flieger D; Renoth S; Beier I; Sauerbruch T; Schmidt-Wolf I
Cell Immunol; 2000 Aug; 204(1):55-63. PubMed ID: 11006018
[TBL] [Abstract] [Full Text] [Related]
15. Functional differentiation of acute myeloid leukaemia blast cells.
Bassøe CF; Halstensen A; Bruserud O
APMIS; 1999 Nov; 107(11):1023-33. PubMed ID: 10598875
[TBL] [Abstract] [Full Text] [Related]
16. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry.
Baer MR; Stewart CC; Lawrence D; Arthur DC; Mrózek K; Strout MP; Davey FR; Schiffer CA; Bloomfield CD
Leukemia; 1998 Mar; 12(3):317-25. PubMed ID: 9529125
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract] [Full Text] [Related]
18. Studies on the susceptibility to NK-mediated lysis and the simultaneous expression of various surface molecules in anthracyclin-treated K562 cells and in four K562 cell clones.
Benoist H; Joly P; Broglio C; Jeannesson P; Idoine O; Dufer J; Desplaces A
Immunol Lett; 1992 Sep; 34(1):45-55. PubMed ID: 1362185
[TBL] [Abstract] [Full Text] [Related]
19. Selection of a panel of monoclonal antibodies for monitoring residual disease in peripheral blood and bone marrow of interferon-treated hairy cell leukaemia patients.
Falini B; Pileri SA; Flenghi L; Liberati M; Stein H; Gerli R; Minelli O; Martelli MF; Lauria F; Poggi S
Br J Haematol; 1990 Dec; 76(4):460-8. PubMed ID: 1702309
[TBL] [Abstract] [Full Text] [Related]
